Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Fenoxazoline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 4/20 | 0.62 |
| ▸ | ADRA2A known ✓ | P08913 | 4/20 | 0.62 |
| ▸ | ADRA2B known ✓ | P18089 | 4/20 | 0.62 |
| ▸ | ADRA2C known ✓ | P18825 | 4/20 | 0.62 |
| ▸ | ADRA1A known ✓ | P35348 | 6/20 | 0.59 |
| ▸ | ADRA1B known ✓ | P35368 | 5/20 | 0.59 |
| ▸ | ADRA1D known ✓ | P25100 | 4/20 | 0.59 |
| ▸ | MAOA known ✓ | P21397 | 3/20 | 0.59 |
| ▸ | MAOB known ✓ | P27338 | 3/20 | 0.59 |
| ▸ | NISCH | Q9Y2I1 | 12/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | THPO | P40225 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fenoxazoline SCHEMBL193061 | 0.99 | NISCH (1.00) | NISCHHTR1AADRA2AADRA2BADRA2C | |
| Fenoxazoline SCHEMBL1650113 | 0.97 | NISCH (0.97) | NISCHHTR1AADRA2AADRA2BADRA2C | |
| Tymazoline SCHEMBL28142132 | 0.89 | NISCH (0.81) | NISCHHTR1AADRA2AADRA2BADRA2C | |
| Fenoxazoline SCHEMBL28086604 | 0.85 | NISCH (0.74) | NISCHHTR1AADRA2AADRA2BADRA2C | |
| Tymazoline SCHEMBL4415590 | 0.83 | NISCH (0.68) | NISCHHTR1AADRA2AADRA2BADRA2C | |
| Tymazoline SCHEMBL250491 | 0.81 | NISCH (0.70) | NISCHHTR1AADRA2AADRA2BADRA2C | |
| Tymazoline SCHEMBL29387735 | 0.81 | NISCH (0.70) | NISCHHTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL3168567 | 0.80 | NISCH (0.73) | NISCHHTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL3169242 | 0.77 | NISCH (0.68) | NISCHHTR1AADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL9654109 | 0.76 | NISCH (0.76) | NISCHHTR1AADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9757376-B2 | Pharmaceutical compositions | GM PHARMACEUTICALS, INC. (US) | 2017-09-12 | — | — | US | claimed |
| EP-1940352-A1 | METHOD OF PREPARING AN AQUEOUS PHARMACEUTICAL COMPOSITION COMPRISING HYDROXYPROPYL METHYLCELLULOSE AND PHARMACEUTICAL C0MP0SITI0NS OBTAINABLE | Fortune Apex Development Limited (VG) | 2008-07-09 | — | — | EP | claimed |
| US-20070104791-A1 | Method of preparing a pharmaceutical composition and pharmaceutical compositions obtainable thereby | FORTUNE APEX DEVELOPMENT LIMITED (VG) | 2007-05-10 | — | — | US | claimed |
| WO-2007049102-A1 | METHOD OF PREPARING AN AQUEOUS PHARMACEUTICAL COMPOSITION COMPRISING HYDROXYPROPYL METHYLCELLULOSE AND PHARMACEUTICAL C0MP0SITI0NS OBTAINABLE | FORTUNE APEX DEVELOPMENT LIMITED (VG) | 2007-05-03 | — | — | WO | claimed |
| EP-1641446-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING AN ANTIHISTAMINE AND A STIMULANT AND USE THEREOF | Pediamed Pharmaceuticals, Inc. (US) | 2006-04-05 | — | — | EP | claimed |
| WO-2004112771-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING AN ANTIHISTAMINE AND A STIMULANT AND USE THEREOF | PEDIAMED PHARMACEUTICALS, INC. (US) | 2004-12-29 | — | — | WO | claimed |
| US-20040259809-A1 | Pharmaceutical compositions including an antihistamine and a stimulant and method of use thereof | PEDIAMED PHARMACEUTICALS, INC. | 2004-12-23 | — | — | US | claimed |
| US-12377075-B2 | Device for internal and external nasal application | HALEON CH SARL (CH) | 2025-08-05 | — | — | US | disclosed |
| EP-4058112-B1 | DEVICE FOR INTERNAL AND EXTERNAL NASAL APPLICATION | GSK CONSUMER HEALTHCARE SARL (CH) | 2023-12-27 | — | — | EP | disclosed |
| US-20220387389-A1 | DEVICE FOR INTERNAL AND EXTERNAL NASAL APPLICATION | HALEON CH SARL (CH) | 2022-12-08 | — | — | US | disclosed |
| EP-4058112-A1 | DEVICE FOR INTERNAL AND EXTERNAL NASAL APPLICATION | GSK Consumer Healthcare SARL (CH) | 2022-09-21 | — | — | EP | disclosed |
| EP-3821927-B1 | DEVICE FOR INTERNAL AND EXTERNAL NASAL APPLICATION | GSK CONSUMER HEALTHCARE SARL (CH) | 2022-01-19 | — | — | EP | disclosed |
| WO-2021094451-A1 | DEVICE FOR INTERNAL AND EXTERNAL NASAL APPLICATION | GSK Consumer Healthcare S.A. (CH) | 2021-05-20 | — | — | WO | disclosed |
| EP-1438942-A1 | An otorhinological drug delivery device | Schering Oy (FI) | 2004-07-21 | — | — | EP | disclosed |
| WO-2004000272-A1 | NASAL COMPOSITIONS COMPRISING A MUCOPOLYSACCHARIDE AND PROPYLENE GLYCOL | NOVARTIS CONSUMER HEALTH S.A. (CH) | 2003-12-31 | — | — | WO | disclosed |
| US-20020193417-A1 | Nasal solutions | SEIDEL MATTHIAS (CH) | 2002-12-19 | — | — | US | disclosed |
| EP-1051155-B1 | NASAL SOLUTIONS | NOVARTIS CONSUMER HEALTH SA (CH) | 2002-06-26 | — | — | EP | disclosed |
| US-20010053775-A1 | Nasal solutions | SEIDEL MATTHIAS (CH) | 2001-12-20 | — | — | US | disclosed |
| EP-1051155-A1 | NASAL SOLUTIONS | Novartis Consumer Health S.A. (CH) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999038492-A1 | NASAL SOLUTIONS | NOVARTIS CONSUMER HEALTH S.A. (CH) | 1999-08-05 | — | — | WO | disclosed |